# Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

> **NCT00634205** · PHASE2 · COMPLETED · sponsor: **European Lung Cancer Working Party** · enrollment: 45 (actual)

## Conditions studied

- Malignant Mesothelioma

## Interventions

- **DRUG:** Valproate plus doxorubicin

## Key facts

- **NCT ID:** NCT00634205
- **Lead sponsor:** European Lung Cancer Working Party
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2009-03
- **Final completion:** 2010-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634205, "Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00634205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*